Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT01962792Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Dec 2013
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ibrutinib in multiple myeloma (MM) (3 arms), sponsored by Pharmacyclics. Primary endpoint: Overall Response Rate up to 4 years. Started Dec 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01962792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962792.